A Regional Monoclonal Antibody Infusion Treatment Center will be located in Nash Texas at 401 Industrial Boulevard and is expected to be operational within a week and offering the treatment known as “Regeneron” in the battle against COVID 19.
Judge Bobby Howell and Texarkana, Texas Mayor Bob Bruggeman received notification this week from the Texas Department of Emergency Management that Texarkana has been chosen as a site for a regional monoclonal antibody infusion treatment center in the battle against COVID-19.
It is anticipated that the site will be operational within the week, and is located at 401 Industrial Boulevard, Nash, TX.
While the treatment is an outpatient process, patients must have a physician’s order to seek the antibody infusion, called Regeneron.
Patients are a candidate for the treatment if they meet one or more of the following criteria:
- 65 years of age or older
- Obesity or being overweight
- Chronic Kidney Disease
- Immunosuppressive Disease
- Receiving Immunosuppressive Treatment
- Cardiovascular disease or hypertension
- Chronic lung diseases
- Sickle Cell Disease
- Neurodevelopmental disorders or other conditions that confer medical complexity
- Having a medical-related technological dependence
If you have received a positive COVID-19 result and think you may be a candidate for this treatment, please consult your physician.
The treatment is not authorized for patients who are hospitalized due to COVID-19, who require oxygen therapy due to COVID-19, or who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.